Stifel Canada Has Weak Estimate for TSE:HLS FY2024 Earnings

HLS Therapeutics Inc. (TSE:HLS) – Equities research analysts at Stifel Canada decreased their FY2024 earnings per share estimates for HLS Therapeutics in a note issued to investors on Tuesday, November 12th. Stifel Canada analyst J. Keywood now forecasts that the company will earn ($0.88) per share for the year, down from their previous estimate of ($0.86). The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.

Separately, Stifel Nicolaus lowered their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Price Performance

Shares of HLS opened at C$3.18 on Friday. The company has a market cap of C$101.09 million, a price-to-earnings ratio of -3.15 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44. The company’s fifty day simple moving average is C$3.55 and its 200 day simple moving average is C$3.54. HLS Therapeutics has a 1-year low of C$3.00 and a 1-year high of C$5.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.